HOPE-3 trial of DMD therapy CAP-1002 to continue as planned
Capricor Therapeutics' CAP-1002 trial for Duchenne muscular dystrophy continues after positive DSMB review. Plans to discuss expedited FDA approval in 2024. CAP-1002, derived from heart cells, aims to improve arm and heart function in DMD patients. Recruitment ongoing; top-line data expected late 2024.
Related Clinical Trials
Reference News
HOPE-3 trial of DMD therapy CAP-1002 to continue as planned
Capricor Therapeutics' CAP-1002 trial for Duchenne muscular dystrophy continues after positive DSMB review. Plans to discuss expedited FDA approval in 2024. CAP-1002, derived from heart cells, aims to improve arm and heart function in DMD patients. Recruitment ongoing; top-line data expected late 2024.